Advances in molecular toxicology. Volume 12 /
Clasificación: | Libro Electrónico |
---|---|
Otros Autores: | , |
Formato: | Electrónico eBook |
Idioma: | Inglés |
Publicado: |
Cambridge, MA :
Academic Press, an imprint of Elsevier,
2018.
|
Colección: | Advances in Molecular Toxicology Ser.
|
Temas: | |
Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Advances in Molecular Toxicology; Copyright; Contents; Contributors; Preface; Chapter One: Toxicology of Inorganic Carcinogens; 1. Introduction; 2. Known Human Carcinogens; 2.1. Arsenic; 2.1.1. Exposure; 2.1.2. ADME properties; 2.1.3. Toxicity; 2.1.4. Mechanisms of toxicity; 2.1.5. Carcinogenicity; 2.2. Beryllium; 2.2.1. Exposure; 2.2.2. ADME properties; 2.2.3. Toxicity; 2.2.4. Carcinogenicity; 2.3. Cadmium; 2.3.1. Exposure; 2.3.2. ADME properties; 2.3.3. Toxicity; 2.3.4. Mechanisms of toxicity; 2.3.5. Carcinogenicity; 2.4. Chromium; 2.4.1. Exposure; 2.4.2. ADME properties.
- 2.4.3. Toxicity2.4.4. Carcinogenesis; 2.5. Nickel; 2.5.1. Exposure; 2.5.2. ADME properties; 2.5.3. Toxicity; 2.5.4. Carcinogenicity; 3. Probably Carcinogenic to Humans; 3.1. Antimony; 3.1.1. Exposure; 3.1.2. ADME properties; 3.1.3. Toxicity; 3.1.4. Carcinogenicity; 3.2. Cobalt; 3.2.1. Exposure; 3.2.2. ADME properties; 3.2.3. Toxicity; 3.2.4. Carcinogenicity; 3.3. Indium; 3.3.1. Exposure; 3.3.2. ADME properties; 3.3.3. Toxicity; 3.3.4. Carcinogenesis; 3.4. Lead; 3.4.1. Exposure; 3.4.2. ADME properties; 3.4.3. Toxicity; 3.4.4. Carcinogenesis; 3.5. Vanadium; 3.5.1. Exposure.
- 4.9. Role of signaling pathways5. Physicochemical Determinants of CNT-Induced Fibrosis; 5.1. Metal content; 5.2. Surface functionalization; 5.3. Dispersion status; 5.4. Length; 6. Conclusions; Acknowledgments; Disclaimers and Declaration of Interest; References; Chapter Three: Chemopreventive Role of Dietary Phytochemicals in Colorectal Cancer; 1. Introduction; 2. Dietary Phytochemicals; 2.1. Quercetin; 2.1.1. Chemical composition and molecular structure; 2.1.2. Sources; 2.1.3. Molecular targets; 2.1.4. Clinical trials; 2.2. Capsaicin; 2.2.1. Chemical composition and molecular structure.
- 2.2.2. Sources2.2.3. Molecular targets; 2.2.4. Clinical trials; 2.3. Epigallocatechin-3-gallate; 2.3.1. Chemical composition and molecular structure; 2.3.2. Sources; 2.3.3. Molecular targets; 2.3.4. Clinical trials; 2.4. Resveratrol; 2.4.1. Chemical composition and molecular structure; 2.4.2. Source; 2.4.3. Molecular targets; 2.4.4. Clinical trials; 2.5. Sulforaphane; 2.5.1. Chemical composition and molecular structure; 2.5.2. Sources; 2.5.3. Molecular targets; 2.5.4. Clinical trials; 2.6. [6]-gingerol; 2.6.1. Chemical composition and molecular structure; 2.6.2. Source.